We support vesicle research.

We’re bringing together leading experts in vesicle analysis to provide solutions for your research. We want our analysis methods in your next grant. We’re happy co-author, collaborate, or fit into your work and applications as needed. Check back soon for downloadable descriptions of our assays, data, NIH biosketches, and more information formatted for grant applications. See the table below for a list of active funding opportunities through the NIH.

Contact Us

Extracellular Vesicle NIH Funding Opportunities

Title FOA Number Institute Start Date End Date
Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) PAR-16-276 NCI 05/23/2016 06/13/2019 R01
Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21) PAR-16-277 NCI 05/23/2016 06/13/2019 R21
Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21) PA-17-157 NIDA 02/08/2017 05/07/2020 R21
Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01) PA-17-155 NIDA 02/08/2017 05/07/2020 R01
Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional) RFA-AI-19-036 NIAID 03/29/2019 07/30/2019 R01
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) PAR-18-947 NCI 09/28/2018 07/11/2021 U01
ExtracellularVesiclesand Substance Use Disorders (R21) PAR-17-242 NIDA 04/04/2017 03/03/2020 R21
ExtracellularVesiclesand Substance Use Disorders (R01) PAR-17-250 NIDA 04/04/2017 03/03/2020 R01
HIV-1 infection of the Central Nervous System (R01) PA-17-100 NIMH 01/05/2017 01/07/2020 R01
New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional) PAR-18-886 NIDDK 08/02/2018 06/01/2021 RC2
Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) PA-19-237 NIAID 04/03/2019 05/07/2022 R21
Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01) PA-16-144 NIDA 03/22/2016 05/07/2019 R01
Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21) PA-16-145 NIDA 03/22/2016 05/07/2019 R21
Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44) PAR-17-035 NCATS 10/27/2016 09/05/2019 R43/R44
Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42) PAR-17-036 NCATS 10/27/2016 09/05/2019 R41/R42
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional) RFA-CA-19-032 NCI 01/24/2019 08/03/2020 R01
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 – Clinical Trial Not Allowed) PA-18-678 NCI 02/23/2018 05/07/2021 R21
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 – Clinical Trial Not Allowed) PA-18-677 NCI 02/23/2018 05/07/2021 R01
Trophoblast Differentiation and Function (R01) PA-16-445 NICHD 09/23/2016 01/07/2020 R01
Dynamic Interactions between Systemic or Non-Neuronal Systems and the Brain in Aging and in Alzheimers Disease (R01) PAR-17-029 NIA 10/21/2016 11/05/2019 R01
Trophoblast Differentiation and Function (R21 Clinical Trial Optional) PA-18-047 NICHD 11/15/2017 01/07/2020 R21
Understanding the Early Development of the Immune System (R01 – Clinical Trial Not Allowed) PAR-18-333 NICHD 10/25/2017 12/05/2019 R01
Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional) PA-18-615 NIDDK 02/01/2018 01/07/2021 R21
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) PA-18-629 NCI 02/05/2018 05/07/2021 R01
Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 – Clinical Trial Not Allowed) PA-18-815 NIGMS 06/05/2018 04/05/2021 R43/R44
Better Defining Growth Medium to Improve Reproducibility of Cell Culture (STTR) (R41/R42 – Clinical Trial Not Allowed) PA-18-816 NIGMS 06/05/2018 04/05/2021 R41/R42
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) PAR-19-113 NCI 12/17/2018 01/07/2022 R01

We use cookies to ensure that you have the best experience on our website. If you continue to use this site we assume that you're happy with it. Dismiss